Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
48.07
+0.43 (0.90%)
At close: Jun 26, 2026, 4:00 PM EDT
48.03
-0.04 (-0.08%)
After-hours: Jun 26, 2026, 7:48 PM EDT
Novo Nordisk Employees
As of December 31, 2025, Novo Nordisk had 69,505 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees decreased by 7,844 or -10.14% compared to the previous year.
Employees
69,505
Change (1Y)
-7,844
Growth (1Y)
-10.14%
Revenue / Employee
$727,566
Profits / Employee
$270,689
Market Cap
214.87B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69,505 | -7,844 | -10.14% |
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
NVO News
- 7 hours ago - Swiss pharma at risk of US trade investigation, industry body says - Reuters
- 9 hours ago - GLP-1s linked to smell and taste impairment in diabetes patients - Reuters
- 9 hours ago - Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage - CNBC
- 1 day ago - An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. - The Motley Fool
- 1 day ago - Novo Nordisk (NVO) Has an Obesity-and-Diabetes Platform Bigger Than a One-Drug Hype Cycle - AlphaStreet
- 1 day ago - Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing - TheFly
- 1 day ago - Hims' obesity drug business may get boost as employers drop coverage - Reuters
- 1 day ago - Novo's top US exec wants more insurance coverage for weight-loss drugs - Reuters